PREVNAR 13® (usually called PCV13, PCV, Pneumococcal conjugate or Pneumococcal on your baby's immunization record) is given to babies, starting at 2 months, and ending at or soon after their 1st birthday, at 2, 4, 6, and 12-15 months of age, to protect against 13 common strains of pneumococcal bacteria.

Pfizer Medical PREVNAR® 13 (pneumococcal 13-valent conjugate vaccine - diphtheria CRM197 protein) | Pfizer Medical Information - US.

For intramuscular injection only. Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers, children and adults.

People who need a pneumonia vaccine should get both shots: first, the PCV13 shot and then the PPSV23 shot a year or more later. For most people, one of each shot should be enough to protect them for their entire lives. Sometimes, you may need a booster shot. Ask your doctor whether you should get one.

CDC recommends the use of PCV13 for the routine vaccination of children younger than 5 years of age (4-dose series at age 2 months, 4 months, 6 months, and 12–15 months) and children 6 years and older without prior PCV13 vaccination who have certain medical conditions that put them at high risk of invasive pneumococcal ...

PREVNAR 20 builds on Pfizer's approved PREVNAR 13 vaccine, and includes seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.

About Prevnar 13 Prevnar 13 was first introduced for use in infants and young children in December 2009 in Europe and in February 2010 in the U.S., and it is now approved for such use in nearly 120 countries worldwide.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age. Dose 1 may be given as early as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks.

If Prevnar 13 is given as part of a routine infant immunization program, a 3-dose (2+1) schedule may be considered. The first dose may be given from the age of 2 months, with a second dose 2 months later, and a third (booster) dose is recommended between 11-12 months of age.

Received PCV13 at Any Age and PPSV3 Before Age 65 Years Give 1 dose of PCV20 or PPSV23. Regardless of vaccine used, their series is complete. The PCV20 dose should be given at least 5 years after the last pneumococcal vaccine. The PPSV23 dose should be given at least 5 years after the last PPSV23 dose.

Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age. Dose 1 may be given as early as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks. The fourth dose should be administered at approximately 12–15 months of age, and at least 2 months after the third dose.

One pneumonia vaccine (Prevnar 13) has an unknown immunity duration, while the other (Pneumovax 23) lasts from five to 10 years. Pneumonia is an infection of the lungs that causes cough, fever, and trouble breathing.